Panel Recommends Listing 9 Substances in Carcinogen Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ARLINGTON, Va-A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on

 ARLINGTON, Va—A scientific panel has recommended listing nine substances as either “known” or “reasonably anticipated” to be human carcinogens. If upheld after review, the substances will be listed in the 10th “Report on Carcinogens,” prepared by the National Toxicology Program (NTP) and scheduled for publication in 2002.

The panel voted to upgrade beryllium and beryllium compounds (substances used in fiber optics, aerospace, and other industrial applications) from “reasonably anticipated” to “known” human carcinogens. They recommended listing vinyl bromide and vinyl fluoride as “known” human carcinogens. Vinyl bromide’s primary use is in making flame-retardant synthetic fibers. Vinyl fluoride is a chemical used in making polyvinylfluoride, which is used in the plastics industry.

The panel also recommended listing two other chemicals used in make products flame resistant as “reasonable anticipated” to be human carcinogens: 2,2-bis-(bromomethyl)l-1,3-propanediol used in unsaturated polyester resins, molded products, and rigid polyurethane foam, and 2,3-dibromo-1-propanol, also found in pesticides and drug preparations.

Three other substances were cited as “reasonably anticipated” to be human carcinogens: dimethylbenzidine dyes used in some textiles and plastics; IQ, found in cooked meat and fish; and styrene-7,8-oxide, use in preparing fragrances.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content